glp-1 course Weight Control Treatment: An Overview of and GLP/GIP Receptor Agonists CEU NA-Understanding-Weight-Loss-1x1-GLP1-101725

In 2025, Novo Nordisks semaglutide awaits several first-time FDA decisions: Injectable GLP-1s 2025 Ozempic for T2DM and peripheral artery disease (PAD) 2H 2025 Wegovy for heart failure with preserved ejection fraction (HFpEF) and obesity Oral GLP-1s October 2025 new indication for oral Rybelsus for secondary CV risk reduction 4Q 2025 the first oral GLP-1 ( oral formulation of Wegovy 25 mg ) for weight loss and weight loss plus secondary CV risk reduction Given the considerable continued growth expected in the GLP-1 pipeline, Prime Therapeutics (Prime) talented team of clinical experts actively monitors this emerging landscape

*3-month, 6-month, or 12-month Ivm membership is required ($74.99/mo)

A study of the Finnish population found that HS patients had a life expectancy 14.7 years shorter than the control group, with cardiovascular disease being the leading cause of death

They're trending towards the sustained decline, and that decline starts to rewire metabolic physiology in several ways

A comprehensive medical weight loss program typically starts with a healthcare professional reviewing your medical history and asking about weight loss goals

Side effect rates were higher in orforglipron patients, but were consistent with injectable GLP-1s